Citations

Mayo Clinic

Showing 10 of 108551 citations.

Abstract 3410: Financial toxicity among patients with advanced prostate cancer in the United States
Singh, Isani , Vaselkiv, Bailey, Enting, Deborah , Nowak, Joel , Kensler, Kevin H. , Nanus, David M. , Heath, Elisabeth I. , Kantoff, Phillip, Kaye, Deborah R. , George, Daniel J. , Mucci, Lorelei A. , Kensler, Kevin , Rencsok, Emily M. , Autio, Karen A. , Morgans, Alicia K. , Dreicer, Robert , Lewis, Brian E. , Sartor, Oliver , Kantoff, Phillip, George, Daniel J.

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 3410-3410

10.1158/1538-7445.am2024-3410 Get It

Abstract Background: Advanced prostate cancer is defined as metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC). Newer and aggressive treatments are leading to increasing lifespans in this population. As such, studying quality of life could have a large impact on the survivorship experience. An important component of quality of life is financial toxicity, defined as the financial burden and distress that can arise for patients and their families because of cancer treatment. Objectives: To understand the prevalence and predictors of financial toxicity in advanced prostate cancer. Methods: IRONMAN (International Registry of Men with Advanced Prostate Cancer) is a prospective cohort of patients with newly diagnosed mHSPC or CRPC enrolling in 15 countries. Financial toxicity was collected using the EORTC QLQ-C30 (“has your physical condition or medical treatment caused you financial difficulties?”) at enrollment and every three months thereafter. For this analysis, we studied 997 patients cared for at 37 US sites enrolled from 7/2017 to 7/2023. We examined baseline and longitudinal reports of financial toxicity across clinical and demographic factors: age at enrollment, race and ethnicity, disease state, marital status, education, employment, military status, and type of health center. We conducted adjusted risk difference analysis and multivariable regression modeling to identify predictors of financial toxicity using a generalized estimating equations approach to calculate odds ratios (OR and 95% confidence intervals, CI). Results: At enrollment, 125 (13%) patients reported experiencing “quite a bit” or “very much” financial toxicity. 21% of Black patients experienced toxicity compared to 10% of White patients. Even after incorporating all other predictors, Black patients experienced 5% (95% CI: 0, 11) greater toxicity than White patients. Independently of other predictors, patients >75 experienced 11% (CI: -17, -4) lower toxicity compared to those <65 years (while patients in the 65-74 group experienced 6% less, CI: -12, 1). Toxicity was 6% greater in patients with mHSPC (CI: 2, 10) than in patients with CRPC, and disabled or unemployed patients were at substantially higher risk. In the multivariable longitudinal analyses, older age (> 75) remained associated with significantly lower odds for financial toxicity (OR: 0.30, 0.15-0.61) while mHSPC (OR: 1.91, 1.14-3.20) and being unemployed (OR: 2.69, 1.03-6.99) or disabled (OR: 5.14, 2.29-11.6) were associated with higher odds. Conclusions: Financial toxicity is prevalent in advanced prostate cancer, especially in patients who are Black, younger than 75, diagnosed with mHSPC, or unemployed/disabled. These results may inform identification of patients at high risk for financial toxicity to support delivery of patient-situation-informed care by clinicians and targeted aid for patients at highest risk. Citation Format: Isani Singh, Bailey Vaselkiv, Emily Rencsok, Karen Autio, Deborah Enting, Alicia Morgans, Joel Nowak, Kevin Kensler, David Nanus, Robert Dreicer, Brian Lewis, Oliver Sartor, Elisabeth Heath, Phillip Kantoff, Deborah Kaye, Daniel George, Lorelei Mucci. Financial toxicity among patients with advanced prostate cancer in the United States [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3410.
Abstract 5753: Milk-derived extracellular nanovesicles: A novel delivery strategy for transcriptome targeting therapies in cholangiocarcinoma
Yu, Mincheng, Carlson, Danielle M. , Werneberg, N., Sample, Jack W. , Kuipers, Hendrien , Carlson, Danielle Marie , Tomlinson, Jennifer L. , Gores, Gregory J. , Smoot, Rory L.

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 5753-5753

10.1158/1538-7445.am2024-5753 Get It

Abstract Introduction: Cholangiocarcinoma (CCA) is an aggressive and heterogenous biliary malignancy. Previous therapeutic shortcomings have encouraged the investigation of new strategies, such as targeted therapeutics. YAP/TAZ, transcriptional coactivators of the hippo pathway, have been implicated in the tumorigenesis of CCA along with the Src familiar kinase, LCK. Milk-derived nanovesicles (MNVs) have emerged as a promising biologic delivery apparatus for hepatobiliary malignancy due to their predilection for hepatic uptake. We sought to investigate the utility of aptamer guided MNVs loaded with short interfering RNA (siRNA) targeting YAP, TAZ, and LCK. Methods: MNVs were prepared and loaded with species-specific siRNA prior to decoration with an epithelial cellular adhesion molecule (EpCAM) targeting aptamer. In vitro studies were performed using murine and human CCA cell lines, SB1 and HuCCT-1, respectively. In vivo studies were carried out using C57BL/6 mice following Institutional Animal Care and Use Committee protocols. Results: We previously validated EpCAM as an effective aptamer demonstrated by increased levels of expression in CCA cell lines using immunoblot, RT-PCR and immunofluorescence. Additionally, in vivo experiments demonstrated excellent biodistribution and affinity for tumor-selective uptake. To evaluate knockdown efficacy, CCA cell lines were incubated with EpCAM aptamer guided MNVs individually targeting YAP, TAZ, and LCK which resulted in downregulation of these targets on immunoblot and RT-PCR. MNVs were then loaded with equal concentrations of siRNA targeting YAP, TAZ, and LCK in combination which resulted in similar degrees of gene downregulation compared with single transcriptome targeting MNVs. Due to the role of YAP/TAZ activation in CCA systemic therapy resistance, we investigated the effect of MNVs loaded with either single target or combinatory target siRNA alongside and in combination with gemcitabine and cisplatin (GemCis). Incubation with both combinatory siRNA and GemCis significantly intensified cell death on Pi/Hoechst staining compared with single target knockdown alone. Similar findings were found using separate assays of cell viability, including ATP luminescent quantitation and caspase 3/7 activity. These data suggest MNV transcriptome targeting may induce a state of cell stress which allows for amplification of chemotherapy treatment effect. Conclusion: Aptamer guided, nanovesicle mediated transcriptome targeting is a promising therapeutic strategy in preclinical CCA models that may potentiate chemotherapy response. Our future direction involves further investigating the role of CCA target downregulation and its effect on the tumor immune microenvironment utilizing aptamer guided nanovesicle delivery and inducible knockdown cell lines. Citation Format: Jack W. Sample, Mincheng Yu, Hendrien Kuipers, Danielle M. Carlson, Nathan W. Werneberg, Jennifer L. Tomlinson, Gregory J. Gores, Rory L. Smoot. Milk-derived extracellular nanovesicles: A novel delivery strategy for transcriptome targeting therapies in cholangiocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5753.
Abstract 5434: A novel combination therapy for lung squamous cell carcinoma
Argo, Ryan A. , Rang, Christine Ratliff, Klinge, Skyeler, Lindemann, Jennifer A. , Searl, Nyla, Fields, Alan P. , Justilien, Verline , Al-Qasrawi, Dania S. , Pandya, Prita

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 5434-5434

10.1158/1538-7445.am2024-5434 Get It

Abstract Lung cancer is the leading cause of cancer deaths in the US. Non-small cell lung cancer (NSCLC) accounts for ~80% of lung cancer cases and is further classified into adenocarcinoma (LUAD), squamous cell carcinoma (LUSC), and large cell carcinoma. New approaches targeting pathways in NSCLC have emerged, resulting in encouraging new treatments that benefit LUAD patients, but very few advances have been made in the treatment options for LUSC which accounts for ~30% of lung cancer cases. NSCLCs, including LUSCs, contain a sub-population of cells that exhibit properties of cancer stem cells (CSCs) and are responsible for tumor initiation, maintenance, therapeutic resistance, and relapse. Therefore, CSCs must be effectively targeted to elicit long lasting therapeutic results in LUSC patients. Our studies have shown that: 1) PKCι is an oncogene and prognostic marker in LUSC; 2) copy number gains (CNGs) of the PKCι gene (PRKCI) drives overexpression of PKCι in 90% of LUSCs; 3) PKCι phosphorylates SOX2, and controls SOX2-mediated transcriptional activation of Hedgehog Acyl Transferase, resulting in Hedgehog (Hh) pathway activation that drives a CSC phenotype in LUSC cells; and 4) the FDA approved compound Auranofin (ANF) is a potent inhibitor of oncogenic PKCι. In this study, we assessed the effect of ANF in combination with the Hh pathway inhibitor, LDE225, on LUSC CSCs and tumor growth. Cell viability, sphere formation and soft agar assays were used to assess the effects of ANF and LDE225 alone or in combination on the growth of LUSC CSCs with PRKCI CNGs or LUAD and LUSC CSCs without PRKCI CNG to determine if PRKCI CNG can be used to predict response to ANF and LDE225 and test the selectivity of response for LUSC. The effects of ANF and LDE225 on the levels of PKCι-Hh signaling components was assessed by qPCR and western blotting. Finally, the efficacy of ANF and LDE225 in combination was evaluated in human primary LUSC patient-derived xenograft (PDX) models that harbor PRKCI CNGs and the ability of PKCι-Hh signaling intermediates to serve as biomarkers of PKCι-Hh pathway inhibition was validated in vivo. We observed a dose-dependent decrease in cell proliferation, clonal expansion and transformed growth in CSCs treated with ANF and LDE225 alone. ANF and LDE225 combined treatment of LUSC CSCs with PRKCI CNGs (but not LUAD or LUSC CSCs without PRKCI CNG) synergistically inhibited CSC phenotypes based on results of combination index analysis. Furthermore, treatment of LUSC PDX models with ANF and LDE225 in combination had a synergistic effect on tumor growth inhibition. Lastly, ANF and LDE225 treatment led to inhibition of PKCι-Hh signaling intermediates demonstrating the on-target effects of treatment. Our data indicate that a PKCι-Hh vertical blockade strategy of combined ANF and LDE225 effectively targets LUSC CSCs and blocks tumor growth in vivo and provides compelling rationale to develop this novel combination strategy further in clinical trials. Citation Format: Dania Alqasrawi, Ryan Argo, Christine Ratliff Rang, Prita Pandya, Skyeler Klinge, Jennifer Lindemann, Nyla Searl, Alan Fields, Verline Justilien. A novel combination therapy for lung squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5434.
Abstract 5444: EGFR missense mutation(s) induce OLIG2 expression to regulate glioma stem cells maintenance and therapeutic resistance
Weaver, Sidney , Miller, Aunay , Blomquist, Mylan, McNamara, James, Orndorff, Keely, Sereduk, Chris , Kloss, Jean , Loftus, Joseph C. , Mehta, Shwetal , Tran, Nhan L. , Tran, Nhan L

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 5444-5444

10.1158/1538-7445.am2024-5444 Get It

Abstract Glioblastoma (GBM) tumors contain a subpopulation of glioma stem cells (GSC) which can escape therapeutic effects through self-renewal and invasion. Epidermal growth factor receptor (EGFR) mutations are the most common alteration in GBM (50%). One example includes extracellular domain missense mutations like G598V, A289V, and R108K (10-15%). These extracellular domain missense mutations increase ligand binding affinity, inducing a highly active receptor. Earlier reports have shown these EGFR missense mutations exhibit therapeutic resistance; however, the molecular mechanism of these missense mutations in GBM remains unknown. In this study, we show high oligodendrocyte transcription factor 2 (OLIG2) expression in GSCs with EGFR-G598V and EGFR-A289V missense mutations. OLIG2 is universally expressed in glioma and essential for reprogramming GBM cells into stem-like tumor cells. Here, we report GSCs with these point mutations display increased self-renewal, growth, invasion, and therapeutic resistance. In addition, EGFR-G598V and EGFR-A289V trigger distinct downstream signaling pathways in GSCs to regulate OLIG2 function. These missense mutation(s) also represent different pathway-based GBM subclassifications, where A289V induces a Neuronal subtype and G598V induces a Glycolytic/Plurimetabolic subtype. We hypothesize that GBM tumors harboring EGFR missense mutations (G598V, A289V) influence stem cell properties via multiple pathways to evade therapeutic effects and inhibiting these different signaling pathways will decrease therapeutic resistance in GBM. Understanding the mechanism of these EGFR mutations may lead to improved therapeutic strategies for GBM patients. Citation Format: Sidney Weaver, Aunay Miller, Mylan Blomquist, James McNamara, Keely Orndorff, Chris Sereduk, Jean Kloss, Joseph Loftus, Shwetal Mehta, Nhan L. Tran. EGFR missense mutation(s) induce OLIG2 expression to regulate glioma stem cells maintenance and therapeutic resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5444.
Abstract 256: A novel transcriptional complex of OLIG2-STAT5 mediates glioma stem cell self renewal and invasion
Miller, Aunay , Cascio, Costanza Lo , Blomquist, Mylan, McNamara, James, Orndorff, Keely, Dufault, Matthew , Sereduk, Christopher, Loftus, Joseph C. , Mehta, Shwetal , Tran, Nhan L. , Tran, Nhan L , Orndorff, Keely, Sereduk, Chris

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 256-256

10.1158/1538-7445.am2024-256 Get It

Abstract Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults, despite current treatment options. One of the major contributing factors to this dismal outcome is a subset of cells called glioma stem cells (GSCs) that are highly tumorigenic, invasive, and resistant to conventional treatments. Thus, studies that focus on the properties of GSC biology are needed to develop novel therapies to improve overall survival. Here we report a novel role of STAT5 in GSC stemness and survival. In GBM tumors, STAT5 has been shown to be active in the infiltrative, residual population of cells remaining post-surgery. Knockdown of STAT5 results in the decrease in GSC stemness and therapeutic resistance. Interestingly, we find that expression of OLIG2, a key cell fate factor important for the tumorigenic potential of GSCs, affects STAT5 activation with a positive correlation between OLIG2 and STAT5 mRNA expression in GBM tumors. Furthermore, we find that in GSCs expressing EGFRvIII, STAT5 interacts with OLIG2 and pharmacological inhibition of STAT5 activation or knockdown of STAT5 expression results in decrease of OLIG2-mediated GSC invasion. Together, these data suggest a novel transcriptional complex, STAT5-OLIG2, in the potential role for GSC survival, maintenance, and invasion. Citation Format: Aunay Miller, Costanza Lo Cascio, Mylan Blomquist, James B. McNamara, Keely Orndorff, Matthew Dufault, Christopher Sereduk, Joseph Loftus, Shwetal Mehta, Nhan L. Tran. A novel transcriptional complex of OLIG2-STAT5 mediates glioma stem cell self renewal and invasion [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 256.
Abstract 2905: Spatial analysis of neuropilin 2 expression in the microenvironment of melanoma
Moore, Raymond M. , Leontovich, Alexey A. , Dicke, Betty A., Stueven, Noah A. , Atherton, Chathu, Nevala, Wendy K. , Dimou, Anastasios , Ward, Caitlin , Guo, Ruifeng, Wang, Chen , Suman, Shankar , Schimke, Jill M. , Atherton, Chathu L., Markovic, Svetomir N.

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 2905-2905

10.1158/1538-7445.am2024-2905 Get It

Abstract Background: Neuropilin 2 (NRP2) is a co-receptor that enhances signaling of growth factor and cytokine receptors and is expressed in tumor and microenvironment (TME) cells in melanoma and other tumors. Neuropilin 2 expression in tumor cells is associated with more aggressive tumors. Expression in tumor associated macrophages enhances efferocytosis and immunologically silent tumor cell death. Methods: Whole excisional lymph node biopsies were obtained from 10 treatment naïve patients with metastatic cutaneous melanoma who subsequently received anti-PD1 treatment. A single 5mm formalin-fixed paraffin embedded tissue section was used to assess a panel of 39 analytes by cyclic multiplex immunofluorescence (MxIF). Fields of view (~1mm2, n=288) were selected from pathologist-annotated regions of the tumor core, tumor-immune interface and adjacent lymphoid tissue. Pixel-based single cell segmentation and a supervised classifier approach was applied to resolve 12 distinct tumor, stromal and immune cell phenotypes and functional states (NRP2 positive or negative) in 1.5 million cells. Results: Tumor recurrence was observed in 6 patients (relapsed), whereas 4 patients were recurrence-free (non-relapsed) during follow up. Among the different cell types, NRP2 expression was more frequent in macrophages (44%), tumor cells (40%), dendritic cells (40%), followed by Tregs (31%) and T helper cells (29%), and less frequent in neutrophils (24%), cytotoxic T cells (23%) and B cells (15%). In colocalization permutation analysis, NRP2 expressing macrophages clustered away from tumor cells in non-relapsed patients while a random spatial distribution of NRP2 expressing macrophages with respect to tumor cells was observed in relapsed patients. In comparing the odds of tumor cell interactions with NRP2-expressing macrophages to those with NRP2 non-expressing macrophages, we found in the tumor:stromal interface (10% tumor cells) that cells from both non-relapsed and relapsed patients were more likely to interact with NRP2 non-expressing macrophages (OR = 0.73, 95% CI = [0.71, 0.75] and OR = 0.56, 95% CI = [0.55, 0.58] for non-relapsed and relapsed patients, respectively). However, in the tumor core (90% tumor cells), tumor cells from relapsed patients had significantly higher odds of interacting with NRP2 expressing macrophages, (OR = 1.15, 95% CI = [1.12, 1.18]), and this was not seen for non-relapsed patients (OR = 0.68, 95% CI = [0.66, 0.71]). In FOVs dominated by tumor cells (75% tumor), tumor cells from relapsed patients had 4.97 times the odds of expressing NRP2 compared to tumor cells from non-relapsed patients (95% CI = [2.23, 11.09], p = 0.0001). Conclusions: These spatial analytics suggest complex interactions among NRP2 expression in tumor and TME of melanoma determining risk for relapse with anti-PD1 treatment. Citation Format: Anastasios Dimou, Raymond M. Moore, Caitlin Ward, Alexey Leontovich, Ruifeng Guo, Chen Wang, Shankar Suman, Betty Dicke, Jill M. Schimke, Noah A. Stueven, Chathu A. Atherton, Wendy Nevala, Svetomir N. Markovic. Spatial analysis of neuropilin 2 expression in the microenvironment of melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2905.
Abstract 4262: AI-driven analysis of collagen characteristics in the tumor immune microenvironment predicts immune checkpoint inhibitors treatment responsiveness in gastric cancer
Kim, Minji , Redekop, Ekaterina , Choi, Yoon-Ho , Aoki, Yu , Shitara, Kohei , Hwang, Tae Hyun , Lee, Sung Hak , Cheong, Jae‐Ho

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 4262-4262

10.1158/1538-7445.am2024-4262 Get It

Abstract Background: Recent studies indicate a correlation between increased stromal composition in tumors and resistance to immune checkpoint inhibitors (ICIs) across various cancer types. Specifically, the extracellular matrix (ECM) within the stromal compartment significantly influence the tumor microenvironment, affecting cancer cell proliferation and immune cell recruitment. However, identifying and quantifying the ECM at the collagen fiber level in whole slide images (WSIs) is challenging due to its inherent heterogeneity and complexity. In this work, we utilized statistical analysis and a deep learning (DL)-based approach to identify and assess collagen in the ECM, examining its characteristics in relation to the ICIs treatment response in gastric cancer. Methods: We analyzed 116 WSIs of hematoxylin and eosin (H&E) stained slides before ICIs treatment from three institutions. Responders were defined as those with a complete response or partial response (N=18); those with stable disease (SD) (N=34) or progressive disease (PD) (N=64) were considered non-responders (N=98). For non-responders, post-treatment H&E slides were available for 21 patients; SD (N=5) and PD (N=16). We applied a DL-based second harmonic generation (SHG) synthesis algorithm to tumor regions identified by a tumor detection model. We then calculated various collagen properties, including volume, fiber orientation and alignment, waviness, straightness, and fiber thickness, based on collagen fiber centerlines extracted from the generated SHG images. An attention-based multiple instance learning (ABMIL) model was trained to automatically predict the treatment response solely based on collagen features. The dataset of 116 pre-treatment slides was divided into training and validation subsets using stratified 3-fold cross-validation. The area under the curve (AUC) was used to assess the performance of the trained models. Results: Collagen fiber features were significantly associated with ICIs response. Notably, ICIs responders have a decrease in collagen waviness and fiber orientation variation (p-value<0.05, by Mann-Whitney U test). Among non-responders, the PD group showed a statistical decrease in waviness after treatment (p-value<0.05, by Mann-Whitney U test). The ABMIL model achieved a mean AUC score of 0.823, with a standard deviation of 0.023. Conclusion: This study provides a comprehensive analysis of collagen in the ECM, and its properties in relation to gastric cancer ICIs response within Tumor Immune Microenvironment. We also developed a model using collagen features and demonstrated high accuracy in predicting treatment response. Citation Format: Minji Kim, Ekaterina Redekop, Yoonho Choi, Sung Hak Lee, Jae-Ho Cheong, Yu Aoki, Kohei Shitara, Tae Hyun Hwang. AI-driven analysis of collagen characteristics in the tumor immune microenvironment predicts immune checkpoint inhibitors treatment responsiveness in gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4262.
Abstract 1310: Social determinants of migrant health factors impacting prostate cancer care and survivorship among sub-Saharan African immigrant men diagnosed with prostate cancer
Asiedu, Gladys B. , Voorhis, Kaitlin Van, Young, Mary Ellen , Erefah, Ebenezer, Agboola, Emmanuel, Odedina, Folakemi T., Dronca, Roxana , Merriweather, Arnola, Hill, Anthony B., Kaninjing, Ernest , Voorhis, Kaitlin Van, Ashing, Kimlin , Rotimi, Solomon O. , Ngufor, Che , McCall, John , Hill, Anthony

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 1310-1310

10.1158/1538-7445.am2024-1310 Get It

Abstract Background: Sub-Saharan African Immigrants (SSAI) represent one of the fastest-growing segments of the immigrant population in the United States (US). Between 2010 and 2018, the SSAI population in the US increased by 53%, significantly outpacing the 12% growth rate for the overall foreign-born population in the US during that time frame. Despite these growing numbers, little is published about the extent to which SSAIs adapt to health behaviors more common in the US or remain immersed in the values, beliefs and practices reflective of their country of origin. Importantly, no study has comprehensively examined the Social Determinants of Health (SDOH) among this population relative to their migration experiences and their influence on health-seeking behaviors and decision-making regarding prostate cancer care and treatment options. Methods: This qualitative study employed grounded theory and the social determinants of migrant heath framework to better understand the needs of SSAI prostate cancer survivors in the United States and how to effectively support these survivors. In-depth interviews were conducted with 8 survivors who live in the states of Florida and Minnesota. Findings: Some participants reported limited access to care and financial challenges paying for drugs. In terms of coping with diagnosis and treatment, most of the participants relied on their faith, a positive outlook about survivorship and support of family members. Some participants relied on the coaching and support of a loved one who experienced prostate cancer in the past. Erectile dysfunction severely impacted the sexual life of most participants as they experienced difficulty getting an erection. Conclusion: Participants expressed the benefit of belonging to support groups with other survivors for social and emotional support. As the number of immigrants from sub-Saharan continue to rise, so too will the demand for culturally tailored care to address and reduce disparities in survivorship among this sub-population. Citation Format: Ernest Kaninjing, Gladys Asiedu, Kaitlin Van Voorhis, Mary Ellen Young, Ebenezer Erefah, Emmanuel Agboola, Folakemi Odedina, Roxana Dronca, Kimlin Ashing, Solomon Rotimi, Che Ngufor, Arnola Merriweather, John McCall, Anthony Hill. Social determinants of migrant health factors impacting prostate cancer care and survivorship among sub-Saharan African immigrant men diagnosed with prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1310.
Abstract 3154: The role of nuclear kinases in pancreatic carcinogenesis
LaRue, Kayla C., Sigafoos, Ashley N. , Flores, Luis F. , Tader, Brooke R , Fernández-Zapico, Martín E.

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 3154-3154

10.1158/1538-7445.am2024-3154 Get It

Abstract Pancreatic ductal adenocarcinoma (PDAC), the most common histological subtype of pancreatic cancer, is a devastating disease predicted to be the second leading cause of cancer deaths in the next 15 years. Thus, there is an urgent need to develop new treatment approaches based on a better understanding of cellular and molecular mechanisms controlling this dismal progression. PDAC development is marked by nuclear morphological changes likely resulting in changes in chromatin organization and gene expression. Oncogenic KRAS, present in more than 90% of tumors, plays a key role in disease initiation and progression and is sufficient to induce these nuclear morphology changes. Work from our lab has identified the nuclear lamina protein Emerin as a mediator of KRAS-induced nuclear morphology changes. Further, a BioID experiment identified a KRAS-induced interaction of Emerin with a group of nuclear kinases belonging to the ribosomal S6 kinase (RSK) and mitogen- and stress- activated protein kinase (MSK) families. In silico analysis identified candidate MSK and RSK phosphorylation sites in Emerin. Thus, we hypothesize that the nuclear kinase families RSK and MSK can act as effectors of the KRAS-Emerin axis to regulate PDAC nuclear morphology. Further studies will be done to confirm if Emerin can be phosphorylated by RSK and MSK, and to validate that this relationship is dependent on oncogenic KRAS signaling and if its nuclear morphological changes are regulated by this GTPase. Overall, this work aims to define a novel signaling axis for RSK and MSK in controlling nuclear dynamics that play a role in disease progression of PDAC, which can lead to the identification of new therapeutic targets. Citation Format: Kayla LaRue, Ashley Sigafoos, Luis Flores, Brooke Tader, Martin Fernandez-Zapico. The role of nuclear kinases in pancreatic carcinogenesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3154.
Abstract 3179: Spindle assembly checkpoint as a therapeutic target for TP53-mutated myeloid neoplasms
Arsana, Arini, Huang, Huixing, Al-Kali, Arief, Shah, Meera

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 3179-3179

10.1158/1538-7445.am2024-3179 Get It

Abstract Introduction TP53-mutated (TP53mut) myeloid neoplasms (MN) are a distinct entity of myeloid neoplasms with no effective therapies and poor survival (Grob et al, Blood 2022). The TP53-deficient state facilitates the downstream dysfunction of the spindle assembly checkpoint (SAC), predisposing to genomic instability. Recently, a SAC protein, threonine tyrosine kinase (TTK), has emerged as an attractive therapeutic target. Upregulation of TTK has been described in various solid tumors. It is stipulated that targeting SAC proteins might result in extreme level of genomic instability that even cancer cells could not tolerate. We hypothesized that inhibition of TTK with a small molecular inhibitor—TTKi may offer a promising therapeutic strategy for TP53mut MN. Method We evaluated relative TTK mRNA expression and its association with TP53mut and complex karyotypes (CK) in the BEAT AML cohort (Tyner et al., 2018). We used myeloid cell lines, OCI-AML-3, THP-1, and U937 cell lines that harbor-near diploid, moderately aneuploid, and highly aneuploid karyotype, respectively. The efficacy of TTKi CFI-402257 (AbMole) was tested using cell viability, apoptosis, and colony-forming unit (CFU) assays using the standard protocol. Finally, we tested the efficacy of CFI-402257 using the diagnostic bone marrow mononuclear cell (BMMC) cells from TP53mut MN patients. Results Among 591 AML patients in the BEAT AML cohort (41.6% diploid, 35.9% non-CK, 22.7% CK), TTK mRNA expression was progressively higher with increasing chromosomal abnormality burden. TTK expression was 1.96-fold higher in TP53mut AML compared to TP53wt AML (P=0.0008). Further stratified by TP53mut VAF, there was a trend towards higher expression of TTK in TP53mut VAF≥50 compared to the cases with VAF<50 (P=0.06). Next, the treatment with TTKi (CFI-402257) led to a dose-dependent reduction in cell viability across all cell lines, with TP53mut cells (U937 and THP-1) being more sensitive than TP53-wildtype (TP53wt) OCI_AML-3 cells. Similarly, TTKi inhibited the CFU potential of THP-1, U937, and OCI-AML-3 cells. Finally, TTKi induced dose-dependent apoptosis in TP53mut MN patient BMMC but not in healthy donors, resulting in a significant reduction in colony-forming potential. Conclusion Overexpression of TTK was strongly associated with TP53mut and CK in AML. Inhibition of TTK-induced dose-dependent apoptosis in all myeloid cell lines tested with TP53mut highly aneuploid cell line (U937)—traditionally the most chemorefractory phenotype—being the most sensitive. TTKi induced preferential and dose-dependent inhibition of viability and cell proliferation potential in TP53mut MN compared to healthy donor cells, implying a therapeutic window. Further pre-clinical and clinical studies are indicated to evaluate SAC inhibition as a therapeutic strategy for TP53mut MN. Citation Format: Arini Arsana, Huixing Huang, Arief Al-Kali, Mithun Shah. Spindle assembly checkpoint as a therapeutic target for TP53-mutated myeloid neoplasms [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3179.